Research programme: anticancer therapeutics - NovoBiotic Pharmaceuticals
Alternative Names: Novo 10Latest Information Update: 04 Sep 2023
At a glance
- Originator NovoBiotic Pharmaceuticals
- Class Antineoplastics; Macrocyclic compounds
- Mechanism of Action DNA modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 04 Sep 2023 Discontinued - Preclinical for Solid tumours in USA (unspecified route) (NovoBiotic Pharmaceuticals pipeline, September 2023)
- 28 Jul 2020 No recent reports of development identified for preclinical development in Solid-tumours in USA
- 22 Jun 2016 Preclinical trials in Solid tumours in USA (unspecified route)